Stockreport

PepGen Announces Positive Initial Results, Including Robust Splicing Correction, from Ongoing FREEDOM-DM1 Trial in Patients with DM1

PepGen Inc.  (PEPG) 
PDF – Significant mean splicing correction of 29.1% following a single dose of PGN-EDODM1 at 10 mg/kg –– PGN-EDODM1 observed to have favorable emerging safety profile –– Con [Read more]